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N euroendocrine tumors (NETs) are a heterogeneous group of neoplasms with varied tumor biology and clinico-pathologic characteristics that may be benign or malignant, with the latter invariably carrying a worse prognosis. Surgical resection is the only curative intervention for NETs. However, most patients have metastatic disease at presentation, necessitating systemic therapy with somatostatin analogs (SSAs), targeted agents or chemotherapy. Despite such interventions, the prognosis for metastatic NETs remains poor: Gastroenteropancreatic (GEP) NETs are associated with 5-year survival ,50%, and treatment is given with palliative intent (1) .
Peptide receptor radionuclide therapy (PRRT) has emerged as an effective treatment of metastatic NETs (2) . PRRT involves administering radiolabeled somatostatin analogs, commonly yttrium Y-90-DOTA-octreotate or lutetium (177)Lu-DOTATATE, which subsequently bind to somatostatin receptors (SSTRs). The receptor and ligand are then internalized, inducing radiation-induced cell death (3) . A recent phase 3 randomized controlled trial showed improved survival benefit of PRRT over long-acting octreotide in midgut NET (4) . Other nonrandomized reports also highlight the success of PRRT in treating a variety of NET subtypes, including lung carcinoid, thymic NET, and metastatic paraganglioma (5, 6) .
Although PRRT is relatively successful, approximately 20% of patients will not respond to treatment. An inability to identify these patients before commencing therapy exposes them to substantial side effects, prohibits their participation in clinical trials of other potentially valuable therapeutic modalities, and has important resource implications. PRRT is associated with myelosuppression, hematological malignancy, and nephrotoxicity. Subacute hematological toxicity is seen in approximately 10% of patients, and 1% to 2% of patients experience myelodysplastic syndrome or acute leukemia. Renal impairment results from proximal tubular reabsorption of the radiolabeled peptide, and 3% to 4% of patients experience grade 3 to 4 toxicity. Determination of nonresponse to therapy requires treatment of up to 12 months at an approximate cost of £40,000 (7) .
In light of these issues, research efforts have focused on identifying a predictor of response to PRRT. An initial study suggested that uptake of radiolabeled somatostatin analog [68Ga]-DOTATOC on positron emission tomography/CT was correlated with time to progression (8), a relationship that was not successfully validated in a subsequent patient cohort (9) . Dual positron emission tomography (incorporating both SSTR imaging and 18 F-fludeoxyglucose imaging of tumor metabolic activity) is suggested to have some prognostic significance, but this is uncertain in the context of PRRT (10) . Very recently, Bodei and colleagues (11) identified a PRRT predictive quotient, derived from a combination of pretreatment, whole-blood gene expression profiling, tumor grade, and circulating chromogranin A (CgA) levels. The PRRT predictive quotient was reported to have a high specificity and sensitivity for predicting the efficacy of PRRT. These data indicate circulating biomarkers, some of which are likely to reflect circulating white blood cell activation, can identify PRRT-responsive patients. However, the requirement for RNA profiling to derive the PRRT quotient presents technical and financial barriers to its rapid and widespread adoption in clinical practice.
The systemic inflammatory response is known to be associated with the development and progression of cancer. The immune response to a solid tumor generates a proinflammatory tumor microenvironment that triggers angiogenesis and invasion and underpins metastasis (12) . Derangements in markers of systemic inflammation, including an elevated neutrophil-to-lymphocyte ratio (NLR) and decreased serum albumin levels, have been shown to confer a poorer prognosis in multiple malignancies (13) (14) (15) . Elevated platelet-to-lymphocyte ratio (PLR) and mean platelet volume have also been linked to more rapid disease progression of gastroenteropancreatic NETs (16), whereas Wiese et al. (17) showed a statistically significant correlation between C-reactive protein (CRP) levels and overall survival within pancreatic NETs. Wu et al. (18) previously demonstrated, within a murine NET xenograft, that PRRT leads to increased infiltration of antigenpresenting cells and natural killer cells into tumors, suggesting a mechanistic role for the inflammatory response in the action of PRRT.
The inflammation-based index (IBI) is derived from the serum CRP and albumin levels, both markers of systemic inflammation. It is prognostic in hepatocellular carcinoma, predicting both overall survival (OS) and response to chemoembolization therapy (19, 20) . In light of the potential association between systemic inflammation and both NET progression and PRRT response, we hypothesized that the combination of positive (CRP) and negative (albumin) acute phase reactants within the IBI score might have a prognostic role in patients with NETs undergoing PRRT.
An association between a biomarker and outcome does not necessarily immediately translate into clinical utility. The predictive accuracy is important and is assessed by using parameters such as sensitivity, specificity, and positive and negative predictive values. However, these do not incorporate any sense of clinical consequences, which may perhaps be viewed as the relative harms of a false-positive and a false-negative prediction (21) . DCA provides a means to evaluate alternative diagnostic and prognostic strategies over a range of risk thresholds (i.e., differing relative weightings of false-positive and false-negative predictions).
The aims of this study were to establish whether IBI was associated with PFS and OS in NETs and to assess, by using DCA, the clinical utility of a treatment strategy using the baseline IBI to determine treatment with PRRT.
Materials and Methods

Patient cohort and clinical data collection
Patients undergoing (177)Lu-DOTATATE PRRT for metastatic NETs at Imperial College Health Care National Health Service Trust between 2008 and 2017 were enrolled into this study. Eligibility for PRRT was decided after multidisciplinary review in accordance with usual clinical practice, and consent was obtained from each patient after full explanation of the purpose and nature of the treatment. Demographic data, including age and sex, alongside primary tumor site, were collected. Hematological data, including CRP, albumin, neutrophil and lymphocyte count, and gut hormone profile were recorded. The gut hormone profile composed of somatostatin, chromogranin A and B, gastrin, glucagon, pancreatic polypeptide, vasoactive intestinal peptide, and 5-hydroxyindoleacetic acid. All hematological and biochemical assays were performed in a certified National Health Service laboratory using standardized laboratory protocols as part of routine clinical care. Ethical approval was granted by the Imperial College Tissue Bank (Reference R14066-3A). Data were collected before commencing treatment (baseline) and after each cycle of PRRT.
PRRT was delivered according to standard practice. Patients received between 5.3 and 8.1 GBq per session; treatment cycles were 12-weekly to a maximum of four cycles. The maximum standardized uptake value of the radiolabeled tracer before treatment was noted. Response was assessed radiologically after the second and fourth cycles by using RECIST (response evaluation criteria in solid tumors) 1.1 criteria (22) . PRRT was halted after the second cycle if patients' disease progressed through treatment or if SSTR tracer uptake intensity was less than that of normal liver parenchyma as assessed by the Krenning score (23) . Patients were reviewed at baseline and then within 2 weeks of completion of the second and fourth treatment cycles.
Derivation of IBI and definition of dynamic changes
The IBI was calculated as previously described (19) . According to predefined thresholds, a single point was awarded for an elevated CRP level (.10 mg/L) or hypoalbuminemia (,35 g/L). Thus, patients with both abnormalities were ascribed a score of 2, patients with one abnormality allocated a score of 1, and patients with normal levels of CRP and albumin were allocated a score of 0. IBI was calculated at baseline and after the second and fourth cycles of PRRT. Dynamic changes in IBI were also assessed as previously described (20) . Two groups were defined. The first group consisted of patients with an improvement in IBI score through treatment (i.e., the score decreased from 2 to 1, from 1 to 0, or 2 to 0) and those retaining a score of 0 both before and after treatment. These patients were defined as having a "normalized" IBI score. Patients in the second group, with a "persistently abnormal" IBI score, were seen to have an increase in IBI score through treatment, or a score of 1 or 2 both before and after treatment.
NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count; PLR was calculated by dividing the absolute platelet count by the absolute lymphocyte count.
Statistical analysis
Time-to-event analyses
Survival times and progression and mortality endpoints were calculated with respect to the commencement of PRRT. Progression was defined by the date of confirmation of radiological progression or cancer-related death; OS was defined by the date of death. Cases were censored at the limit of follow-up.
Associations between demographic characteristics, hematological and biochemical values, and survival were tested by using Cox regression analysis. For the purposes of statistical analysis, continuous variables were dichotomized by division into two populations defined by the median value. Univariate Cox regression models were fitted for each variable in turn. Independent associations were tested by fitting multivariable Cox regression models incorporating variables significantly associated on univariate analysis. Multivariable models were specified by using stepwise backward elimination. P , 0.05 was used for entry into the model and P . 0.1 for removal. Statistical significance was defined using a threshold P , 0.05.
Assessment of clinical utility
Clinical utility was assessed by using net benefit as derived by DCA: The approach and the appropriate circumstances in which to apply it are detailed by Vickers et al. (21, 24) . A decision model was specified by using an abnormal baseline IBI (.0) as an opt-out criterion with disease progression 12 months after commencement of treatment as the endpoint. Net benefit is calculated by subtracting the "false-positive" patients from the "true-positive" patients, divided by the total number of patients studied. This is then offset against a function of the relative harms (i.e., impact on survival) of treatment, or of withholding treatment, for a range of threshold probabilities from 0 to 1. Graphically, a clinically useful model will be to the right of the "treat all" line and above the horizontal "treat none" line. Patients with incomplete progression status at 12 months were excluded from this analysis.
Statistical analyses were performed by using SPSS statistical package, version 24 (IBM, Chicago, IL) and R studio, version 
Results
Patient characteristics
Fifty-five patients were enrolled. Just over half were male (29 of 55, 53%) with a median age of 56 years (range, 16 to 79 years). Most NETs were of bowel or pancreatic origin (29 of 55, 54%). Clinical and pathological features are summarized in Table 1 . Median PFS was 21.2 months (range, 1.3 to 76.9 months), and median OS was 27.9 months (range, 1.8 to 96 months). All 55 patients had $one PRRT cycle; 42 (76%) patients completed all four cycles. Seven (13%) patients withdrew because of disease progression and five (9%) because of a lack of tracer uptake on target lesions seen on SSTR imaging. Partial response was observed in 15 patients (28%), stable disease in 24 (44%) patients, and progressive disease in seven (13%) patients. Response was not evaluable in eight (15%) patients. The median blood somatostatin level at baseline was 55 pg/mL (range, 10 to 731 pg/mL). Tumors were grade 1 in 20 patients (36%), grade 2 in 16 (29%) patients, grade 3 in two (4%) patients, and grade unknown in 17 (31%) patients. The median Ki67 percentage value was 3% (range, 1% to 35%).
Survival analyses and IBI
IBI score was available for 53 (96%) patients at baseline, 50 (91%) patients after two PRRT cycles, and 38 (69%) patients after three to four cycles. Of the 53 patients with an available baseline IBI score, 35 (66%) had a score of 0, nine (17%) had a score of 1, and nine (17%) had a score of 2 ( Table 2) . Raised baseline IBI score was associated with greater risk for disease progression [ Fig. 1A ; hazard ratio (HR), 14.2 (95% CI, 5.25 to 38.5), P , 0.001]. Mean PFS was 51.7 (95% CI, 41.6 to 71.8), 11.8 (95% CI, 7.61 to 15.9), and 9.04 (95% CI, 4.63 to 13.4) months in patients with baseline IBI scores of 0, 1, and 2, respectively. Elevated IBI score at baseline was also associated with increased mortality [ Fig. 1B Dynamic changes in IBI following PRRT are illustrated in Fig. 2 . Between baseline and after one or two cycles of PRRT, 35 patients had normalized IBI score, whereas 15 remained persistently abnormal. The impact of change in IBI on survival was assessed. A persistently abnormal score was associated with inferior PFS [ Fig. 1C (Fig. 1D) . A persistently abnormal IBI score between baseline and after the third or fourth cycles of PRRT was significantly associated with reduced PFS [ Fig. 1E ; HR, 3.23 (95% CI, 1.19 to 8.74), P = 0.02] and reduced OS [ Fig. 1F ; HR, 5.80 (95% CI, 1.6.3 to 20.7), P , 0.01].
Increased tumor grade was associated with worse PFS (P = 0.003) and OS (P = 0.01), whereas elevated baseline somatostatin level was associated with poorer OS (P = 0.01) and PFS (P = 0.01). Elevated baseline CgA level was not associated with a statistically significant change in PFS or OS (25) . Similarly, baseline levels of the gut hormones Chromogranin B, gastrin, glucagon, pancreatic polypeptide, vasoactive intestinal peptide and 5-hydroxyindoleacetic acid were not associated with statistically significant changes in PFS or OS (data not shown).
Other factors that were analyzed for association with survival included maximum standardized uptake value at baseline; the presence of liver metastases; the presence of extrahepatic metastases; the subgroup of NET (gastroenteropancreatic vs nongastroenteropancreatic NETs); and baseline NLR and PLR. None of these variables emerged as statistically significant univariate predictors of either OS or PFS on univariate analysis (25) .
Multivariable analysis confirmed significant, independent associations for baseline IBI score [HR, 3.22 
DCA
Net benefit of using IBI over current inclusion criteria in terms of predicting disease progression at 12 months was evaluated in 51 patients. In two patients, follow-up data were less than 12 months and so they were excluded from the analysis. An opt-out rule based on an abnormal baseline IBI score demonstrated greater net benefit than a treat-all strategy between risk thresholds of approximately 3% and 58% ( Fig. 3; Table 3 ). At the point that the net benefit of treating all or no patients was equal, namely a threshold probability of 21.6%, the net benefit of IBI was calculated as 0.73 (95% CI, 0.44 to 0.89).
Discussion
As a group of conditions, metastatic NETs remain challenging to treat and have a consistently poor prognosis. PRRT represents a promising therapy, but it seems effective in only a subgroup of patients. Treatment is expensive and its side effects potentially very toxic, creating an as yet unmet need for techniques to predict response to treatment. Moreover, patients given months of ineffectual treatment are all the while prevented from enrollment into other experimental clinical trials (26) .
In recent years, an increasing body of evidence has linked systemic inflammation to worse survival in patients with cancer, and a variety of validated biomarkers for prognosis that incorporate the systemic inflammatory response exist across several tumor types, including within NETs (27) (28) (29) . The IBI combines two markers of the acute phase response: elevated CRP and low serum albumin. In this study, we have highlighted that when these measures are combined in this manner, there is a link between markers of systemic inflammation and poor prognosis in metastatic NETs. Pretreatment, elevated IBI scores are associated with inferior OS and PFS in patients treated with PRRT. This suggests a potential role for IBI in aiding patient selection for PRRT by highlighting patients likely to have an objective response to therapy.
We underline the clinical significance of this finding with DCA. This method takes into account relative benefits and harms and is used to demonstrate utility of a given model, in this case the ability of IBI to predict for disease progression at 12 months. When analyzing the ability of IBI to predict for disease progression, for example, we show a net benefit of 0.73 at a threshold probability of 21.6% (the point at which net benefit of treating all patients and no patients was equal). This means that if the decision to treat with PRRT was made by using IBI, rather than offering it to all eligible patients, at this risk threshold there would be a net increase of 73 true-negative results per 100 patients without an increase in the number of false-negative results compared with a treat-all strategy.
Follow-up data were incomplete for two patients who died of a cause unrelated to their disease before imaging assessment 12 months after commencing treatment. Nonetheless, these findings are of particular note considering the relatively modest sample size of this study.
Furthermore, our finding that a persistently elevated IBI score through PRRT was associated with inferior PFS and OS may indicate that serial reassessment of IBI after, for example, two of four treatments, might highlight patients who are likely to have little benefit from further PRRT.
Discovery of biomarkers to aid patient selection for PRRT has recently been an active area of research. Bodei et al. (11) recently developed the PRRT predictive quotient (PPQ). This score is based on the whole-blood expression signature of eight genes (ARAF, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3), Figure 2 . Schematic showing the proportion of patients with IBI scores of 0, 1, and 2 changing through treatment. Scores that decreased after treatment or remained at 0 were "normalized," whereas "persistently abnormal" scores increased or remained at 1 or 2 after treatment.
combined with tumor grade and circulating CgA levels and predicts PRRT response with high sensitivity and specificity (11) . Significant net benefit was demonstrated across a wide range of threshold probabilities on DCA. The biomarkers that make up the IBI are not included within the PPQ, which is associated with response and clinical benefit. IBI may provide a useful adjunct to the PPQ as a method of prescreening or as additional biomarker data, which might improve clinical utility.
Compared with PPQ, IBI is a simple biomarker that is easily calculable and derived from data readily available and routinely obtained in clinical practice. Furthermore, it does not require biopsy, imaging, or genetic analysis and can be obtained at low cost even within areas with fewer health care resources. IBI scoring for PRRT candidates could be incorporated into routine clinical practice with immediate effect. Patients would avoid unnecessary treatment toxicity, and health care systems would benefit from a reduction in health care costs without negatively impacting outcomes.
Our findings indicate that integrating markers of the systemic inflammatory response within the PPQ may increase its sensitivity and specificity as a predictor of PRRT efficacy. Interestingly, we demonstrated a relationship between elevated somatostatin levels and decreased PFS (P , 0.02) but found no significant association between CgA (currently included within the PPQ) levels and response (P = 0.187) within our cohort. This may be a function of differences in cohort composition or size and requires further study.
Given that white blood cells make up a large number of the circulating cells that contain genetic material, and the genomic signature for PRRT was derived from RNA isolated from circulating blood, the changes in RNA expression seen in the PPQ developed by Bodei et al. may in fact represent a facet of the systemic inflammatory response to cancer.
We acknowledge that our sample size and the retrospective nature of our study limit the current clinical utility of our data; given the rarity of the disease and the limited number of patients receiving PRRT, this problem is common with other similar studies in this field. Furthermore, information about tumor grade was missing in 17 of 55 patients in our study; this variable nonetheless emerged as a significant independent predictor of survival on univariate and multivariate analysis. In addition, it would have been useful to directly compare IBI scores with OS and PFS to those of a matched population of patients who did not receive PRRT. We suggest that an adequately powered prospective analysis should be undertaken to validate the prognostic value of IBI: such a study should include other potentially important phenotypic factors, such as the rate of tumor growth before PRRT and the nature of pre-PRRT treatments.
In conclusion, our results show a clear role for IBI in predicting prognosis for patients treated with PRRT across a range of NETs. Validation in an independent cohort of patients should be performed to confirm these findings prior to integration into clinical practice. Subject to this, our data indicate that IBI is a biomarker for survival and radiological response for metastatic NETs treated with PRRT that is inexpensive, is readily available, and could be rapidly instituted in clinical practice with almost instantaneous clinical benefit. Figure 3 . Decision curve for IBI to predict PFS 12 mo after treatment with PRRT in patients with metastatic NETs. Standardized net benefit (y-axis) reflects the clinical utility of a given biomarker, 1.0 being the most useful and negative net benefit representing net harm done by using the biomarker. The thick gray line is the net benefit of treating no patients, the thin gray line is the benefit of treating patients according to current inclusion criteria, and the black line demonstrates the net benefit of treating patients according to their baseline IBI score. 
